Emergent Biosolutions: Q3 Earnings Snapshot
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- EBS Emergent BioSolutions-15.6% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Emergent BioSolutions belongs to, so it often moves with news about it.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and is a peer of Emergent BioSolutions in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson is a peer of Emergent BioSolutions in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+9.0% 30d
AbbVie is a peer of Emergent BioSolutions in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Emergent BioSolutions in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.3% 30d
Abbott Laboratories is a peer of Emergent BioSolutions in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| EBS | +3.74% | +12.54% | base | -2.65% | -8.02% | -8.96% | -5.76% |
| XLV | -2.95% | -0.31% | base | -0.34% | +2.73% | +0.31% | +0.13% |
| LLY | -9.22% | -2.71% | base | -0.17% | +0.45% | -2.64% | -4.04% |
| JNJ | -0.68% | +1.70% | base | -1.63% | +2.13% | +0.67% | +2.13% |
| ABBV | -0.84% | +0.67% | base | -1.01% | +1.62% | +0.12% | +0.94% |
| MRK | -4.45% | -1.43% | base | -2.55% | +1.29% | -0.75% | -1.14% |
| ABT | -6.49% | -5.19% | base | -0.80% | +5.08% | +2.96% | -0.28% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Emergent Biosolutions: Q3 Earnings Snapshot Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -1.01% | final price |
| ABBV | the next day | +1.62% | final price |
| ABBV | two days later | +0.12% | final price |
| ABBV | three days later | +0.94% | final price |
| ABBV | three days earlier | +0.67% | final price |
| ABBV | five days earlier | -0.84% | final price |
| ABT | that day | -0.80% | final price |
| ABT | the next day | +5.08% | final price |
| ABT | two days later | +2.96% | final price |
| ABT | three days later | -0.28% | final price |
| ABT | three days earlier | -5.19% | final price |
| ABT | five days earlier | -6.49% | final price |
| EBS | that day | -2.65% | final price |
| EBS | the next day | -8.02% | final price |
| EBS | two days later | -8.96% | final price |
| EBS | three days later | -5.76% | final price |
| EBS | three days earlier | +12.54% | final price |
| EBS | five days earlier | +3.74% | final price |
| JNJ | that day | -1.63% | final price |
| JNJ | the next day | +2.13% | final price |
| JNJ | two days later | +0.67% | final price |
| JNJ | three days later | +2.13% | final price |
| JNJ | three days earlier | +1.70% | final price |
| JNJ | five days earlier | -0.68% | final price |
| LLY | that day | -0.17% | final price |
| LLY | the next day | +0.45% | final price |
| LLY | two days later | -2.64% | final price |
| LLY | three days later | -4.04% | final price |
| LLY | three days earlier | -2.71% | final price |
| LLY | five days earlier | -9.22% | final price |
| MRK | that day | -2.55% | final price |
| MRK | the next day | +1.29% | final price |
| MRK | two days later | -0.75% | final price |
| MRK | three days later | -1.14% | final price |
| MRK | three days earlier | -1.43% | final price |
| MRK | five days earlier | -4.45% | final price |
| XLV | that day | -0.34% | final price |
| XLV | the next day | +2.73% | final price |
| XLV | two days later | +0.31% | final price |
| XLV | three days later | +0.13% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 50 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 32 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 46 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 47 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Emergent Biosolutions: Q3 Earnings Snapshot” looks
12 out of 100
“Emergent Biosolutions: Q3 Earnings Snapshot” scores 12 out of 100. The score uses 1 sources.